Lemborexant: First Approval

Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation

(2019) Carsten Theodor Beuckmann et al.   SLEEP

0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea

(2019) Jocelyn Cheng et al.   SLEEP

0371 Lemborexant Treatment for Insomnia in Phase 3: Impact on Disease Severity

(2019) Tom Roth et al.   SLEEP

0370 Patient-reported Sleep Onset and Sleep Maintenance: Pooled Analyses of Lemborexant Phase 3 Studies

(2019) Phyllis C Zee et al.   SLEEP

0367 Lemborexant Treatment for Insomnia: 6-month Safety

(2019) Mikko Kärppä et al.   SLEEP

Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2

(2019) J. Yardley et al.   SLEEP MEDICINE

Impact of lemborexant treatment on the patient global impression - insomnia scale

(2019) C. Drake et al.   SLEEP MEDICINE

The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases

(2018) Chunmei Wang et al.   Frontiers in Molecular Neuroscience

Insomnia in Elderly Patients: Recommendations for Pharmacological Management

(2018) Vivien C. Abad et al.   DRUGS & AGING

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

(2018) Annemiek Vermeeren et al.   SLEEP

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study

(2017) Patricia Murphy et al.   Journal of Clinical Sleep Medicine

In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist

(2017) Carsten Theodor Beuckmann et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant

(2016) Patricia J. Murphy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist

(2015) Yu Yoshida et al.   JOURNAL OF MEDICINAL CHEMISTRY

Orexin Receptors: Pharmacology and Therapeutic Opportunities

(2011) Thomas E. Scammell et al.   Annual Review of Pharmacology and Toxicology